Cyclophosphamide

Adult T-Cell Leukemia/Lymphoma

John ReneauSmall moleculePhase 4 / ApprovedActive

BBB

76/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 63/ 100
Competitive Position: 95/ 100

Competitive context

32 Active assets in the Adult T-Cell Leukemia/Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Dexasone The First Affiliated Hospital of Soochow University	Phase 2	BBB
Fludarabine John Reneau	Phase 2	BBB
Etoposide National Cancer Institute (NCI)	Phase 2	BBB
LENALIDOMIDE National Cancer Institute (NCI)	Phase 2	BBB
Rituximab Northwestern University	Phase 2	BBB

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

79 / 100

mycosis fungoidesActive

BBB

Indicative · Phase 4

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.